X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1688) 1688
Publication (163) 163
Book Review (36) 36
Conference Proceeding (2) 2
Magazine Article (2) 2
Book Chapter (1) 1
Data Set (1) 1
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1273) 1273
oncology (1212) 1212
index medicus (984) 984
chemotherapy (830) 830
female (794) 794
2nd-line treatment (756) 756
middle aged (694) 694
aged (659) 659
male (601) 601
antineoplastic combined chemotherapy protocols - therapeutic use (558) 558
adult (538) 538
cancer (524) 524
2nd-line chemotherapy (426) 426
treatment outcome (417) 417
cisplatin (331) 331
lung neoplasms - drug therapy (324) 324
2nd-line therapy (320) 320
antineoplastic agents - therapeutic use (317) 317
docetaxel (297) 297
pharmacology & pharmacy (291) 291
care and treatment (286) 286
phase-ii trial (285) 285
paclitaxel (281) 281
open-label (278) 278
disease-free survival (274) 274
gemcitabine (256) 256
antineoplastic combined chemotherapy protocols - adverse effects (252) 252
phase-iii trial (249) 249
aged, 80 and over (243) 243
carcinoma, non-small-cell lung - drug therapy (238) 238
trial (230) 230
1st-line treatment (229) 229
carcinoma (211) 211
double-blind (208) 208
research (196) 196
clinical trials (194) 194
metastasis (192) 192
deoxycytidine - analogs & derivatives (191) 191
therapy (191) 191
phase-ii (186) 186
survival rate (186) 186
survival (183) 183
prognosis (176) 176
neoplasm staging (171) 171
drug administration schedule (169) 169
medicine & public health (164) 164
drug therapy (163) 163
retrospective studies (163) 163
survival analysis (160) 160
supportive care (157) 157
neoplasm metastasis (152) 152
carboplatin (151) 151
hematology, oncology and palliative medicine (149) 149
combination (147) 147
lung neoplasms - pathology (145) 145
deoxycytidine - administration & dosage (144) 144
lung cancer (142) 142
analysis (141) 141
ovarian neoplasms - drug therapy (139) 139
neoplasm recurrence, local - drug therapy (138) 138
irinotecan (135) 135
salvage therapy (134) 134
antineoplastic combined chemotherapy protocols - administration & dosage (133) 133
respiratory system (131) 131
oxaliplatin (130) 130
paclitaxel - administration & dosage (129) 129
non-small cell lung cancer (127) 127
erlotinib (125) 125
lung cancer, non-small cell (125) 125
bevacizumab (124) 124
cell lung-cancer (123) 123
antineoplastic agents (122) 122
drug resistance, neoplasm (122) 122
disease progression (120) 120
multicenter (119) 119
randomized phase-iii (119) 119
taxoids - administration & dosage (117) 117
cancer therapies (116) 116
adenocarcinoma - drug therapy (115) 115
cancer research (115) 115
adenocarcinoma (113) 113
antimitotic agents (113) 113
topotecan (112) 112
randomized-trial (110) 110
cisplatin - administration & dosage (108) 108
antineoplastic agents - adverse effects (107) 107
1st-line therapy (106) 106
antineoplastic agents - administration & dosage (105) 105
combination chemotherapy (104) 104
stomach neoplasms - drug therapy (104) 104
ovarian cancer (101) 101
carcinoma, non-small-cell lung - pathology (100) 100
2nd-line (99) 99
camptothecin - analogs & derivatives (99) 99
lung neoplasms - mortality (99) 99
fluorouracil - administration & dosage (98) 98
patients (98) 98
fluorouracil (97) 97
gefitinib (96) 96
kaplan-meier estimate (94) 94
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Urology, The, ISSN 0022-5347, 2016, Volume 195, Issue 2, pp. 254 - 263
Journal Article
The Lancet, ISSN 0140-6736, 06/2003, Volume 361, Issue 9375, pp. 2099 - 2106
Journal Article
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2017, Volume 12, Issue 4, pp. 752 - 762
Journal Article
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2010, Volume 116, Issue 23, pp. 5407 - 5414
BACKGROUND: This study evaluated whether progression‐free interval (PFI) following primary chemotherapy (PCT) was predictive of overall survival (OS) after... 
ancillary data analysis | endometrial cancer | salvage chemotherapy | Gynecologic Oncology Group | chemotherapy | DOXORUBICIN PLUS CISPLATIN | PERSISTENT | ADENOCARCINOMA | FILGRASTIM | 2ND-LINE CHEMOTHERAPY | OVARIAN-CANCER | PACLITAXEL | PHASE-II TRIAL | THERAPY | ONCOLOGY | CARCINOMA
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 1, pp. 48 - 55
Journal Article